Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 10/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.35 |
| ▸ | KDR | P35968 | 8/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126277 | 0.89 | KDM4E (0.36) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL2694828 | 0.82 | MEN1 (0.38) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL8142536 | 0.81 | TSHR (0.48) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL16125136 | 0.80 | KDM4E (0.37) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL4200809 | 0.80 | KDM4E (0.37) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL4215152 | 0.80 | SORD (0.42) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL20309635 | 0.80 | KDM4E (0.37) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL8142567 | 0.79 | SMN1; SMN2 (0.47) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL14334526 | 0.79 | FGFR1 (0.40) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL4074571 | 0.79 | MEN1 (0.43) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | KDM4E 4564/4885GAA 4070/4885FGFR1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.